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Abstract
High throughput sequencing is discovering many likely causative genetic variants in individuals with cerebral palsy. Some inves-
tigators have suggested that this changes the clinical diagnosis of cerebral palsy and that these individuals should be removed from
this diagnostic category. Cerebral palsy is a neurodevelopmental disorder diagnosed on clinical signs, not etiology. All
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nonprogressive permanent disorders of movement and posture attributed to disturbances that occurred in the developing fetal
and infant brain can be described as “cerebral palsy.” This definition of cerebral palsy should not be changed, whatever the cause.
Reasons include stability, utility and accuracy of cerebral palsy registers, direct access to services, financial and social support
specifically offered to families with cerebral palsy, and community understanding of the clinical diagnosis. Other neurodevelop-
mental disorders, for example, epilepsy, have not changed the diagnosis when genomic causes are found. The clinical diagnosis of
cerebral palsy should remain, should prompt appropriate genetic studies and can subsequently be subclassified by etiology.
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The International Cerebral Palsy Genomics Consortium
(ICPGC) recently held its 2nd Annual Meeting in Zhengzhou,
China (April 13-14, 2018). Among the scientific highlights of
the meeting was the growing recognition that a large number of
individuals with cerebral palsy harbor potentially clinically
relevant genomic findings. This insight generated robust dis-
cussion about whether a clinical diagnosis of cerebral palsy
should be revised given genetic findings. The clear consensus
was that the clinical diagnosis of cerebral palsy should not
change despite the identification of a genetic or nongenetic
cause if the person exhibits a nonprogressive permanent dis-
order of movement and posture. The Clinical Consensus State-
ment timeline is shown in Table 1.1
We acknowledge the difficulties in a clinical definition
when there are no common signs or pathology. Cerebral palsy
is conceptualized as a neurodevelopmental disorder affecting
the motor domain and is a clinical diagnosis based on signs,
symptoms, and medical history rather than laboratory investi-
gations or diagnostically supportive neuroimaging. Cerebral
palsy is currently defined as “a group of permanent disorders
of the development of movement and posture, causing activity
limitation, that are attributed to non-progressive disturbances
that occurred in the developing fetal or infant brain. The motor
disorders of cerebral palsy are often accompanied by distur-
bances of sensation, perception, cognition, communication,
and behaviour, by epilepsy, and by secondary musculoskeletal
problems.”2
The term cerebral palsy is agnostic to underlying etiology.
There are many known and most probably many unknown
genetic and environmental risk factors and causal pathways.3
The numerous etiologies and heterogeneous nature of cerebral
palsy were acknowledged in 1992 by Mutch et al who further
described it as “an umbrella term covering a group of non-
progressive, but often changing, motor impairment syndromes
secondary to lesions or anomalies of the brain arising in the
early stages of its development.”4 Given its historical under-
pinnings, cerebral palsy was believed to be due primarily to
sentinel events around the time of delivery such as acute
hypoxia at birth. However, in the modern era, current data
suggest that well-defined severe acute intrapartum hypoxia
using international criteria can account for only a minority of
cases of cerebral palsy in high-income countries.5-8 Thus, in
many individuals, the pathogenesis of cerebral palsy is unclear
although prenatal risk factors are often identified.
Retaining the idea that cerebral palsy inherently implies
either a recognized or occult hypoxia will only contribute to
confusion around whether to continue to use the clinical diag-
nosis of cerebral palsy in an individual with a nonprogressive
motor disorder, when a pathogenic genetic variant (or indeed
any other putative “cause” for the cerebral palsy) has been
identified.
Accumulating evidence shows that a potential genetic etiol-
ogy can be identified in between 10% and 30% of individuals
with cerebral palsy, because of both de novo and inherited
genetic variants,9-14 more commonly among children without
recognized environmental risk factors. Some of these identified
genetic variants have been found in genes previously impli-
cated in neurodevelopmental disorders such as TUBA1A and
L1CAM.13 This has raised questions as to whether these indi-
viduals should continue to carry the clinical diagnosis of cere-
bral palsy after a molecular genetic diagnosis.
For the majority of these individuals, it seems most appro-
priate to continue to use the cerebral palsy clinical diagnosis
rather than relabel such cases as cerebral palsy
“masqueraders,” “mimics,” “phenocopies,” or “cerebral
palsy-like.”15-17 Many rare inherited nonprogressive metabolic
disorders may present with a cerebral palsy phenotype and may
later be diagnosed with metabolic screening and genomic
sequencing.18-20 These too should remain classified as cerebral
palsy with a metabolic subtype. The importance here is that this
diagnosis improves counseling, prognosis, and often specific
therapy. “Reclassification” attempts may be misguided unless
the newly identified etiology of the disorder is inconsistent
with the clinical definition of cerebral palsy, as in the case of
neurodegenerative diseases.1 And, consistent with the 2007
consensus definition,1 and reflected in the inclusion/exclusion
criteria of Cerebral Palsy register programs internationally,21,22
a cerebral palsy diagnosis should be reconsidered in the case of
a progressive disorder such as a mitochondrial disease.22
Individual cases of cerebral palsy may have both genetic and
nongenetic etiologies and may overlap with other neurodeve-
lopmental disorders.23 Redefining the clinical diagnosis of cer-
ebral palsy after the identification of an underlying pathogenic
genetic variant may be problematic to both cerebral palsy
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research and clinical care. As with other disorders character-
ized by symptom clusters such as autism, intellectual disability,
and epilepsy, the primary unifying clinical descriptor remains
unchanged after an etiology is defined.
Whether the causal pathway relates to genetics, infection,
hypoxia or prematurity, if the child exhibits any early-onset
nonprogressive movement disorder that has been assessed by
a trained clinician and diagnosed as cerebral palsy, this clinical
diagnosis should not be changed because of an identification of
a putative genetic etiology. However, identifying a genetic
etiology provides another layer of understanding of disease
pathology, opening opportunities to refine genetic and prog-
nostic counseling and offering the hope of precision treatments
targeted to the disease mechanism.
We offer the following reasons for diagnostic consistency
and continuity:
Globally, cerebral palsy registries exist that monitor the
jurisdictional birth prevalence and provide critical epi-
demiologic information of broad public health impor-
tance.24 These registries link to research projects,
including clinical trials. Removing large numbers of
cases with genetic variants would artificially lower the
prevalence of cerebral palsy and may encourage false
claims that different interventions contributed to this
reduction.
Many cerebral palsy clinics explicitly follow children
with cerebral palsy for the early detection, monitoring,
and management of hip subluxation, contractures, sco-
liosis, pain, or other comorbidities.25 Removing the
clinical diagnosis of cerebral palsy may inadvertently
cause these children to miss out on these vital preven-
tion and surveillance programs.
In many countries, families with a child diagnosed with
cerebral palsy are eligible for diagnosis-based govern-
mental financial support. Although all types of disabil-
ity, regardless of cause, should receive support,
removing the cerebral palsy diagnosis could disenfran-
chise these individuals and their families from this
support. Designated cerebral palsy advocacy groups
also support these families. Removing the designation
of “cerebral palsy” could potentially make the child
ineligible for such assistance. Withdrawing the cere-
bral palsy clinical diagnosis may also contribute to
distrust and medicolegal issues, implying “my child
was misdiagnosed as having cerebral palsy.”
The existing clinical diagnosis of cerebral palsy aligns
with modern definitions of other neurodevelopmental
disorders where etiology is distinguished from clinical
diagnosis, for example, epilepsy.26,27 Using cerebral
palsy as a clinical diagnosis that is independent of
etiology urges clinicians to seek an underlying cause,
which may have important implications for treatment
and family planning.
Lastly, when children with cerebral palsy are described to
others by their parents, it may be more meaningful to
say “my child has cerebral palsy (due to a genetic
cause)” than “my child has TUBA1A syndrome” or any
of a large number of variants/causal pathways cur-
rently being found in cerebral palsy. Individuals with
cerebral palsy due to genetic mutations and their fam-
ilies may connect with both the cerebral palsy and rare
disease communities, but these associations are both
likely to be of benefit and not mutually exclusive.
As we learn more about the various pathways to cerebral
palsy through modern neuroimaging, genomics, and
mechanism-based studies, individuals with cerebral palsy may
be more accurately classified and understood by adding “due
to” and “caused by” to the description—for example, cerebral
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palsy due to lissencephaly caused by a TUBA1A mutation. As
the majority of identified cerebral palsy genetic etiologies are
rare monogenetic diseases, cerebral palsy nosologies and clas-
sifications will need to increasingly align to rare diseases cod-
ing and ontologies, such as Orphanet Classifications and the
Orphanet Rare Diseases Ontology (http://www.orphadata.org/
cgi-bin/inc/about.inc.php.). For example, recent progress in
understanding the penetrance in disease-causing mutations will
enhance our understanding of the genetic architecture and the
association between genotype and disease phenotype.28 This
research affirms that complex causal pathways are at play and
this in turn reinforces the need for phenotypically driven clin-
ical descriptions, as well as more accurately identified etiolo-
gies, to facilitate precision medicine. This “layering” of
clinical, etiologic, and mechanism-based descriptions reflects
the continuing progress of clinical medicine and its ever-
evolving understanding of the biological processes that under-
lie disease/disorders.
In epilepsy, a disorder that is frequently comorbid with
cerebral palsy, genetic diagnoses have extended the etiologic
understanding. Since the identification of the first idiopathic
epilepsy gene in 1995, more than 260 other genes now28 con-
tribute to the knowledge of this condition.29,30 Before then,
many doubted the relevance of epileptic genetic factors. The
identification of genetic etiologies for epilepsy did not alter
the primary clinical diagnosis; instead, it refined it, and has
led to improvements in epilepsy phenotyping, improved epi-
lepsy classification, and fostered progress toward precision
medicine.26,27 Maintaining the clinical diagnosis of cerebral
palsy will encourage the development of improved nomencla-
ture and classification for these disorders, ultimately enhan-
cing further genetic and other etiologic discoveries and
informing clinical care.
Cerebral palsy is, and should remain, an umbrella concept
and clinical diagnosis that encompasses the diverse motor phe-
notypes/topographies and etiologies of this disorder (Figure 1).
There is room under this umbrella for classification by known
and unknown causal pathways and in the future by other
mechanisms, including epigenetic, multigenic, and environ-
mental triggers in those with genetic susceptibility. Given the
recent exciting progress in identifying a genetic etiology in a
significant proportion of cerebral palsy, it is appropriate now to
consider genomic testing in the etiologic workup of cerebral
palsy.8-14 There are increasing numbers of initiatives addres-
sing this, which strengthens the relevance and timeliness of an
approach that embraces genomic medicine while retaining fun-
damental clinical principles based on a unifying framework.31
Individuals with cerebral palsy are best served by a dynamic
phenotypic framework, informed through an increasingly pre-
cise (molecular) understanding of causation. To this end, the
creation of an international database of genetic variants
involved in cerebral palsy causation is in progress and will
be made available by the International Cerebral Palsy Genomic
Consortium (www.icpgc.org.32
In sum, identifying genetic etiologies or any other specific
etiology should not change the clinical diagnosis of cerebral
palsy, and individuals with this diagnosis should continue to be
included in cerebral palsy registries and receive the rehabilita-
tion, health care, financial, and social support that they and
their families deserve.
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